In this video, Motley Fool health care analyst Max Macaluso takes a closer look at Amarin (AMRN -1.20%), which recently received approval from the Food and Drug Administration for its triglyceride-lowering drug Vascepa. The drug's excellent safety profile compared to other competitive drugs within the same space should definitely catch the eye of investors. However, because Vascepa hasn't received NCE status yet -- which would grant the company an extra two years of marketing exclusivity on top of the initial three -- enthusiasm may be somewhat tempered for the short term.